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ORIGINAL ARTICLE
Efficacy of topical imiquimod 3.75% in the treatment of actinic keratosis of the
scalp in immunosuppressed patients: our case series
E. Zavattaroa, F. Veroneseb , G. Landuccib, V. Tarantinob and P. Savoiab
aDepartment of Translational Medicine, University of Eastern Piedmont, Novara, Italy; bDepartment of Health Science, University of Eastern
Piedmont, Novara, Italy
ABSTRACT
Background: Actinic keratoses (AK) represent common cutaneous lesions, appearing in ‘Field canceriza-
tion areas’ and potentially evolving toward invasive neoplasm. Immunosuppressed patients frequently
develop numerous and aggressive AKs.
Aim: In this observational study, we report our experience with topical Imiquimod 3.75% as ‘Field-
directed therapy’ in a cohort of immunosuppressed patients.
Methods: A group of 13 immunosuppressed patients presenting multiple AKs of the balding scalp was
treated with topical Imiquimod 3.75%. Each patient underwent clinical examination at fixed timepoints
during the treatment (T0, T14, T28, T42) and eight weeks after the end.
Results: In our cohort, the treatment was well tolerated, with minimal local adverse events. We observed
a good clinical response, in terms of Lmax lesions (maximum lesion count during the course of therapy)
and of AK clearance. In our group, 46% of patients showed no detectable lesions at the end of the obser-
vation period, and this result was maintained up to 1 year after the end of treatment.
Conclusion: Topical Imiquimod 3.75% represents an effective and safe treatment for multiple AK of the
scalp also in immunosuppressed patients. To the best of our knowledge, this is the first report on the use
of this drug in this category of subjects.
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Nonmelanoma skin cancers (NMSCs) represent the most frequent
neoplasms in Caucasian subjects. In this group, various clinical
entities are included; among them, actinic keratoses (AKs) are one
of the most common, thus representing more than 20% of the
diagnoses in the Dermatology Outpatient settings (1). They can
be observed predominantly in fair-skinned individuals in sun-
exposed areas, and their number increases with age. The term
‘Skin Cancerization Field’ is commonly used to indicate areas of
chronically UV-damaged skin, where, from a histological point of
view, there is a large number of atypical keratinocytes, with the
potential to progress to ‘in situ’ carcinoma or invasive and meta-
stasizing malignancy (Squamous Cell Carcinoma¼ SCC) (2,3).
Clinical examination of these cutaneous areas reveals the pres-
ence of hypo/hyperpigmentation, atrophy, erythema, and of AKs
in different grades of differentiation.
Main risk factors for the development of NMSCs are repre-
sented by light skin, older age, beta-HPV infection, or immuno-
suppression, but, currently, UV-radiation exposure and its effect at
a molecular level are considered as the major factors related to
the development of this neoplasm.
In Italy, as recently reported, the prevalence of AKs is of 27.4%,
typically increasing in elderly patients (Odds Ratio 4.8 in people
aging 46–60 years; OR 41.5 in subjects >70 years) (4).
Immunosuppression is another important risk factor, and this is
further confirmed by the high incidence of AKs in organ trans-
planted recipients (OTRs), reaching up to 250-fold higher that in
immunocompetent subjects (5).
Moreover, due to the immunosuppressive status and in consid-
eration of the photosensitivity of some immunosuppressant drugs,
multiple and relapsing AKs are often detectable in OTRs, with a
consequent high risk of development of Non-Melanoma Skin
Cancer (6–9).
In recent years, the field cancerization concept has reached
even more importance, thus leading to the need of its treatment
in order to eradicate subclinical lesions, in contrast to the therapy
of every single visible lesion (‘lesion-directed’ therapy) (2,3,7).
Imiquimod (IMI) is an agonist of toll-like receptors 7 and 8 for
topical use, able to stimulate the cutaneous immune response
(10). In Italy, it was approved at the concentration of 5% for the
treatment of condylomata acuminata and basal cell carcinomas;
more recently, IMI 3.75% cream has also been approved in the
field therapy of AKs, in sun-exposed areas such as the face or the
balding scalp (11). In immunocompetent patients, its clinical effect
consists in the detection and clearing of subclinical lesions, which
become visible during treatment. On this basis, the concept of
Lmax is used to define the maximum lesion count during the
course of therapy (12,13).
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In the present study, we report our experience concerning the
treatment of AKs of the scalp with topical IMI 3.75% in a cohort
of immunosuppressed patients.
Patients and methods
We consecutively enrolled a group of immunosuppressed patients
affected by AKs of the scalp, among those referred to Outpatients
Clinic in the Dermatology Unit of the University Hospital of
Novara, Italy. The inclusion criteria for the study consisted in: (i)
immunosuppression status (OTRs or subjects previously submitted
to long-term chemotherapy for neoplasia) (ii) age 18 years or
older; (iii) the presence of multiple AKs of the scalp (3 clinically
visible lesions), thus requiring a ‘Field Cancerization’ treatment; iv)
capability to understand the correct use and to self-administer
the therapy with IMI 3.75%.
Patients presenting hyperkeratotic lesions requiring surgical
excision and/or not able/available to use the prescribed therapy
were excluded.
The treatment modalities have been explained to each
enrolled patient: 250mg of cream containing IMI 3.75% has been
applied on the affected area (scalp), ranging between 50 and
100 cm2, every day for 14 days (first cycle), then the same treat-
ment was repeated (second cycle) after two weeks of rest.
Simultaneously, the local and expected effects of the therapy (ery-
thema, exudate, scabbing/crusting, skin erosion or ulceration) and
how to manage the skin reactions were clearly explained. Patients
underwent to clinical examination before starting the therapy
(baseline, T0) and then at fixed time-points: at the end of the first
cycle (T14), before and after the second cycle (T28 and T42,
respectively) and 8weeks after the end of the treatment; we cal-
culate Lmax for each patient during treatment. At the 8 weeks’
time point, all residual AKs were treated with cryotherapy, in
order to obtain the complete clearance of the cancerization field.
Subsequently, each patient underwent to periodic follow-up visits,
whose frequency (varying from 3 to 6months) was established
either on the basis of clinical response to IMI 3.75% or to patient
clinical history (i.e. previous NMSCs or the presence of other sus-
picious cutaneous lesions). All lesions were counted at baseline
and at every clinical examination; clinical photography of the
treated site was taken.
The present study has been conducted in accordance with
Good Clinical Practice, the principles of the Declaration of Helsinki
and all relevant local regulations.
Results
A total of 13 immunosuppressed patients were enrolled in the pre-
sent study; all were males, with a mean age of 68.1 years at the
time of the treatment (range 49–80 years). Eleven subjects were
OTRs: in detail 8 patients had previously undergone kidney and
three liver transplantation; mean transplant duration was 11.2 years
(range 6months–19years). The remaining two patients from our
cohort previously received chemotherapy (and/or radiotherapy) for
hematological neoplasms; one patient had also been submitted to
autologous stem cell transplantation. All the enrolled patients had
been previously affected by multiple NMSCs that required different
treatments, thus including cryotherapy, topical therapy (i.e. diclofe-
nac sodium 3% or ingenol mebutate) and/or surgery. The clinical
data of patients, including immunosuppressive therapy, the cause
of organ failure or other comorbidities are summarized in Table 1.
At baseline, the median number of clinically evident lesions
was 8 (range 3–30); at the end of the first cycle (T14, timepoint
that in all patients corresponded to the Lmax) it was 14 (range
Table 1. Patient characteristics.
Patient Gender Age Transplanted organ, date Immunosuppressive therapya Cause of Organ failure/Comorbidities Previous Skin Cancerb
1 M 50 Kidney, 2008c b (previously ael) Kidney tuberculosis Multiple NMSCs
2 M 72 Kidney, 2018 ael Polycystic kidney disease Multiple Aks
3 M 71 Kidney, 2005 ab Polycystic kidney disease /MGUSd Multiple NMSCs
4 M 77 Kidney, 2004 ael Polycystic kidney disease Multiple NMSCs
5 M 58 Kidney, 2007 al (previously ael) Hypertensive kidney failure/Multiple myeloma Multiple NMSCs
6 M 77 Kidney, 1999 ael Kidney failure of uncertain origin Multiple NMSCs
7 M 66 Kidney, 2013 ael Focal glomerulonephritis Multiple Aks
8 M 80 Kidney, 2005 al Kidney failure of uncertain origin Multiple NMSCs
9 M 77 Liver, 2003 al HCV-related cirrhosis, HCCd Multiple Aks
10 M 71 Liver, 2009 bl (previously al) HBV-related cirrhosis /Ocular melanoma Multiple NMSCs
11 M 72 Liver, 2004 dl HBV- related cirrhosis Multiple NMSCs
12 M 66 – VTD, then Multiple myeloma Multiple sclerosis Multiple NMSCs
ASCT MELe
13 M 49 – ABVDþ RT Stage 2 Hodgkin lymphoma Multiple NMSCs
beta IFN (2011)e
aImmunosuppressive therapy: a: tacrolimus; b: mTORinhibitor; d: Cyclosporin; e: Mofetil Mychophenolate; f: azatioprin; l: steroid.
bNMSC: Nonmelanoma skin cancer; AK: actinic keratosis.
cPatient returned to hemodyalisis 3months before Imiquimod therapy.
dMGUS: Monoclonal Gammopathy of Undetermined Significance; HCC: Hepatocellular carcinoma.
eVTD: Bortezomid–Talidomide–Dexamethasone; ASCT: autologous stem cell transplant; MEL: melphalan; ABVD: Adriamycin-Bleomycin-Vinblastine-Dacarbazine; RT:
radiotherapy; beta IFN: beta Interferon.
Table 2. Number of detectable lesions for each patient at different timepoints.
Number of detectable lesions
Patient T0 T14 Lmax T28 T42 Follow-up (8 weeks)
1 19 26 9 9 4
2 30 45 13 15 7
3 12 14 7 7 0
4 10 22 9 12 4
5 6 12 4 10 0
6 15 25 10 13 8
7 8 10 5 7 3
8 8 14 7 8 4
9 8 10 6 8 3
10 3 4 2 2 0
11 4 8 3 2 0
12 16 30 5 7 0
13 3 6 4 5 0
Median no of AKs 8 14 9 8 3
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4–45). The median number of AKs at T28 was 9 and at T42 was 8.
After 8weeks of follow-up, the median number of lesions was 3;
in detail, 6/13 patients (46%) achieved the complete clearance of
the lesions (no AKs detectable), 5/13 (38%) had a 50% reduction
and 2/13 (16) had a reduction of about 80% in the number of the
lesions previously observed (Table 2). At the current time, all
patients (both those treated with imiquimod alone and those
treated with cryotherapy of residual lesions) show complete
remission of the treated area after a median follow-up of
6months (range 3–12months).
Representative clinical images of our patients are reported in
Figure 1. Lesion count expressed as median at different time
points is reported in the graph in Figure 2.
All patients of our cohort completed the treatment, and no
severe adverse effects occurred; only one patient complained of
asthenia and mild fatigue during the first cycle of therapy that
promptly disappeared during the rest period. In no patient, we
have observed abnormalities in routine blood tests nor alterations
in serum immunosuppressant level during the course of treat-
ment, and no signs of local infections were displayed. Local skin
reaction occurred mainly during the first cycle of therapy. Patients
were trained to apply wet dress with a Saline solution (0.9%
sodium chloride) in the treated site twice daily, hence, only in
two cases with a severe reaction, the use of topical antibiotics for
a few days was required. Any patient reported pain related to the
therapy, only a mild itching was felt in the course of skin reaction,
mainly after the first cycle of therapy (Lmax timepoint). The local
reactions and their severity for each patient are reported in
Table 3.
Discussion
In the present study, we report our experience with topical
Imiquimod 3.75% for the treatment of AKs of the balding scalp in
a cohort of immunosuppressed patients. To the best of our know-
ledge, this is the first study evaluating the efficacy and tolerability
of this Imiquimod concentration in OTRs and/or in immunosup-
pressed patients (so far, in literature, only the use of IMI 5% has
been reported). Our results confirmed the good efficacy of IMI
3.75% also in this category of subjects, without significant differ-
ences in local skin reactions and/or drug adverse effects with
respect to immunocompetent individuals (12–13). Another import-
ant point to be underlined was, in our case series, the lack of
interactions between IMI 3.75% and immunosuppressive therapy,
similar to what reported for IMI 5%.
The fact that OTRs have a higher prevalence of AKs and signifi-
cant risk to develop NMSCs (namely invasive SCCs), compared to
the immunocompetent subjects supports the high need for a
proper treatment of the cancerization field, thus including the
chance to clear also the subclinical lesions. On this basis, while
the 5% IMI must be applied exclusively to single lesions, IMI
3.75% has to be used on the whole cancerization field, thus lead-
ing to detect, reveal and destroy subclinical lesions, that represent
the expression of keratinocyte damage prone to neoplastic trans-
formation within a short time. So, treating the field cancerization
would allow preventing the appearance of further AKs and poten-
tially invasive SCCs. However, further scientific studies are
needed in order to compare the efficacy of IMI 3.75% with other
therapies currently recommended in AKs and Cancerization Field,
Figure 1. Clinical images of a group of patients at different timepoints corresponding to (a) T0, (b) T14, end of first cycle of treatment (L max) and (c) follow up
8weeks after the end of therapy.
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especially in the setting represented by OTRs and immunosup-
pressed patients.
In literature, several guidelines for the treatment of actinic
keratosis are currently available, often showing differences
between various countries (14,15); recently, Richard and coll. pub-
lished a review on the management of AKs in high-risk patients.
In this latter category, OTRs, as well as subjects suffering from
hematological neoplasms (i.e. chronic lymphocytic leukemia) are
included, and the authors recommend an early treatment of the
lesions, through the use of Photodynamic Therapy (PDT), laser
ablation and/or curettage and surgery, together with a regular
and strict follow–up (16).
However, best treatments in these high-risk patients are repre-
sented by the ‘Field-directed therapies’, that means those treat-
ments able not only to eradicate visible lesions but also to allow
a complete clearance of the cancerization field.
About this, there are data supporting the use of PDT in the
treatment of AKs in OTRs; and a recent clinical trial compares PDT
with IMI 5%, showing a higher efficacy of PDT (17,18). In a recent
review, PDT shows the highest rates of complete clearance
(40–76.4%), followed by IMI 5% (27.5–62.1%), diclofenac (41%)
and 5-Fluorouracil (11%), in OTRs (19).
The use of Imiquimod in OTRs is still controversial and it is not
allowed worldwide: in fact, the European Medicines Agency
advises the cutaneous treatment in OTRs only for areas smaller
than 60 cm2, unless this cutoff is related to the concentration of
5% (20). The use of this molecule was initially limited due to the
potential role of the immune system activators in inducing graft
rejection. Indeed, the only major adverse event reported in OTRs
treated with IMI is represented by a case of acute tubular necrosis
in a kidney transplant patient, who receive Imiquimod 5% cream
for diffuse viral warts. However, the total size of the treated area is
not reported, and the effect displayed more than 40 days after the
beginning of therapy (21). On the other hand, there are several
reports about the use of Imiquimod 5% as safety and successful
treatment for actinic keratosis in OTRs (22–24). In any case, all
patients included in these studies were treated with IMI at higher
concentrations (5%) and for longer periods than in our case series
To date, studies reporting the use of IMI 3.75% against AKs
have highlighted a good efficacy of the treatment together with
the scarcity of adverse events, even if there are no reports on
OTRs (13,25).
Even if our study is limited by the small number of subjects
and by the evaluation conducted only clinically, our experience
highlights the efficacy and safety of this therapy, together with
good results at subsequent follow-up controls, a distance of
up to 1 year also in OTR. We are aware that further studies
involving large cohorts of OTRs and instrumental evaluation
(i.e. confocal microscopy) are needed, but we believe that this is
a relevant contribution in order to stress the need for a com-
plete treatment of the Field Cancerization in immunosuppressed
patients.
Acknowledgements
The authors wish to thank all the patients that participate to the
present study.
Figure 2. Graph showing the lesion counts expressed as median value of all the patients at different examined timepoints.
Table 3. Severity of local reactions.
Local reactions
Patient T14 T42 Follow-up (8 weeks)
1 moderate mild resolved
2 severe mild resolved
3 mild mild resolved
4 moderate mild resolved
5 mild moderate resolved
6 moderate mild resolved
7 mild mild resolved
8 mild mild resolved
9 mild mild resolved
10 mild mild resolved
11 mild mild resolved
12 severe mild resolved
13 mild mild resolved
Mild: erythema; Moderate: erythema, crusts; Severe: erythema, edema, crusts
and serum.
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